Development and validation of a methotrexate adherence assay

BACKGROUND: The first-line therapy for rheumatoid arthritis (RA) is weekly oral methotrexate (MTX) at low dosages (7.5–25 mg/week). However, ~40% of patients are non-adherent which may explain why some do not respond and need to start more expensive biological therapies. To monitor adherence more ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Bluett, James, Riba-Garcia, Isabel, Verstappen, Suzanne M M, Wendling, Thierry, Ogungbenro, Kayode, Unwin, Richard D, Barton, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788879/
https://www.ncbi.nlm.nih.gov/pubmed/31167761
http://dx.doi.org/10.1136/annrheumdis-2019-215446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788879/
https://www.ncbi.nlm.nih.gov/pubmed/31167761
http://dx.doi.org/10.1136/annrheumdis-2019-215446

Ejemplares similares